{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"description":"A serious TEAE was any untoward medical occurrence in a clinical trial participant after first dose of IP irrespective of a causal relationship with the IP(s), that resulted in death, was immediately life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or another medically important serious event.","groups":[{"description":"Participants with relapsed or refractory multiple myeloma received a triplet combination of KRd.\n\nCarfilzomib was administered as a 10-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day treatment cycles. The starting dose of carfilzomib was 20 mg/m\\^2 on Days 1 and 2, and if tolerated, escalated to a target dose of 27 mg/m\\^2 starting on Day 8 of cycle 1 and thereafter. From cycle 13, the Day 8 and Day 9 doses of carfilzomib were omitted. After cycle 18, carfilzomib was discontinued.\n\nLenalidomide 25 mg was taken orally on Days 1 to 21 and dexamethasone 40 mg by mouth or IV infusion on Days 1, 8, 15, and 22 of repeated 28-day treatment cycles.","id":"OG000","title":"Carfilzomib, Lenalidomide and Dexamethasone (KRd)"},{"description":"Participants with relapsed or refractory multiple myeloma received a doublet combination of Kd.\n\nCarfilzomib was administered as a 30-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day treatment cycles. The starting dose of carfilzomib was 20 mg/m\\^2 on Days 1 and 2, and if tolerated, was escalated to a target dose of 56 mg/m\\^2 starting on Day 8 of cycle 1 and thereafter.\n\nDexamethasone 20 mg was taken by mouth or IV infusion on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle.","id":"OG001","title":"Carfilzomib and Dexamethasone (Kd)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all enrolled participants who received at least one dose of IP.","reportingStatus":"POSTED","timeFrame":"From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months","title":"Number of Participants Who Experienced Serious TEAEs","type":"PRIMARY","unitOfMeasure":"Participants"}